Author | Lightnews

Reposted by Andy Wolfe

gouthamnarla @gouthamnarla.bsky.social · 13d

Exciting new finding about the role of PP2A molecular glues in overcoming resistant to broad classes of MAPK inhibitors in KRAS driven cancers
JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer www.jci.org/articles/vie...

JCI - A PP2A molecular glue overcomes ras/mapk inhibitor resistance in kras-mutant non-small cell lung cancer

www.jci.org

2 7

Andy Wolfe @andrewlwolfe.bsky.social · 12d

Huge congrats to this year’s cohort of @damonrunyon SPARK postbacs -- especially @huntercollege alumni Subyeta Chowdhury and NY-RaMP alumni Imani Williams! damonrunyon.org/news/entries/8337/Damon%20Runyon%20announces%20newest%20class%20of%20SPARK%20Scholars

Damon Runyon announces newest class of SPARK Scholars

www.damonrunyon.org

Reposted by Andy Wolfe

Damon Runyon Cancer Research Foundation @damonrunyon.org · Jul 23

Damon Runyon mentor-mentee duo Piro Lito, MD, PhD, and Antonio Cuevas-Navarro, PhD, have developed a new approach to treating RAS-driven cancers, such as colorectal and pancreatic. Rather than inhibiting the cancerous protein, their drug restores its natural function. Read more:

New Discoveries and Honors in Cancer Research | Damon Runyon

www.damonrunyon.org

1 1

Reposted by Andy Wolfe

Hunter College @huntercollege.bsky.social · 20d

Great stuff! Hunter College osteosarcoma researcher Shahana Mahajan has published a paper with new findings that have possible applications to many types of cancers. More: journals.plos.org/plosone/arti... #MihiCuraFuturi

Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity

KRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also...

journals.plos.org

1 1

Andy Wolfe @andrewlwolfe.bsky.social · Oct 1

See How E.V. Road Trips Went From Impossible to Easy www.nytimes.com/interactive/...

See How E.V. Road Trips Went From Impossible to Easy (Gift Article)

There are a lot more fast chargers than there used to be. Look up what that could mean for a route near you.

www.nytimes.com

1 1

Reposted by Andy Wolfe

Ruben Sebastian @rubensebas.bsky.social · Aug 14

Encouraging phase 1 results of an off-the-shelf, lymph node targeted #cancer vaccine targeting common #KRAS mutations (G12D, G12R) in pancreatic and colorectal cancer from Elicio $ELTX, @mskcancercenter.bsky.social, @mdanderson.bsky.social‪‬, UCLA & clinical collabs

www.nature.com/articles/s41...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine

In the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal ...

www.nature.com

2 7

Reposted by Andy Wolfe

IMP @impvienna.bsky.social · Sep 12

Congratulations to our @obenaufa.bsky.social on receiving the highly prestigious Dr. Josef Steiner Cancer Research Award 2025! 🎉

Read more in this interview with Anna: www.imp.ac.at/news/article...

1 26 170

Andy Wolfe @andrewlwolfe.bsky.social · Aug 12

I am thrilled that our findings about using the Ras inhibitor daraxonrasib against osteosarcoma were just published in PLOS ONE! Many congrats to my co-authors Okkeun Jung, Angelene Soto, and Shahana Mahajan. dx.plos.org/10.1371/jour...

Model of daraxonrasib action in osteosarcoma from Jung et al PLOS ONE 2025

4

Reposted by Andy Wolfe

University of California @uofcalifornia.bsky.social · Aug 8

The federal government’s demand of $1 billion from @UCLA would devastate the nation’s best public university, cut off life-saving care, halt tech and economic growth and reduce educational access.

Stand with UC to protect our vital mission: www.universityofcalifornia.edu/get-involved...

Stand Up for UC

www.universityofcalifornia.edu

57 170

Andy Wolfe @andrewlwolfe.bsky.social · Jul 29

www.nytimes.com/2025/07/29/c...

In Game-Changing Climate Rollback, E.P.A. Aims to Kill a Bedrock Scientific Finding

www.nytimes.com

1

Andy Wolfe @andrewlwolfe.bsky.social · Jul 25

Exciting work!

Sciences @sciences.skyfleet.blue · Jul 24

Molecular glues that facilitate RAS binding to PI3Kα promote glucose uptake without insulin

Science, Volume 389, Issue 6758 , Page 402-408, July 2025.

www.science.org

1

Reposted by Andy Wolfe

Hunter College @huntercollege.bsky.social · Jul 7

@cuny.edu Research in Focus looks at the work of Hunter College’s Climatologist and Professor of Geography and Environmental Science, William Solecki, who shows how we can design our public spaces to mitigate global warming. Read about it here: www.cuny.edu/news/resilie...

25 Colleges. One University.

www.cuny.edu

1 2

Reposted by Andy Wolfe

Hunter College @huntercollege.bsky.social · Jun 24

Congratulations and bon voyage to Hunter College alumni Sajida Ahmed, Alison Juray, Andrew Loka, and Alp Doymaz, who will be traveling all over the world during the 2025 - 2026 academic year through the Fulbright Program! #HunterPride hunter.cuny.edu/news/four-fr...

1 3

Reposted by Andy Wolfe

Kyrie Pappas, PhD @kyriepappas.bsky.social · Jun 12

Excited to share our recent work published in PNAS last week uncovering the molecular mechanisms of PARP inhibitor resistance in BRCA2-deficient metastatic castration-resistant prostate cancer (mCRPC). Check out our manuscript!

The Charles Sawyers Lab @sawyerslabmskcc.bsky.social · Jun 10

Just out: BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function | PNAS www.pnas.org/doi/10.1073/... @mskcancercenter.bsky.social @kyriepappas.bsky.social #SawyersLabMSKCC

PNAS

Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...

www.pnas.org

1 4

Andy Wolfe @andrewlwolfe.bsky.social · May 29

Our amazing lab team, Spring 2025! A huge congratulations to the lab members about to earn their undergraduate degree, finish their postbaccalaureate program, begin graduate school, and begin medical school.

Wolfe Lab at Hunter College group photo Spring 2025

1 6

Andy Wolfe @andrewlwolfe.bsky.social · May 10

Very excited that this work was published in PNAS today!
www.pnas.org/doi/10.1073/...

Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine | PNAS

RAS is the most frequently mutated oncogene in cancer. RAS proteins show high sequence similarities in their G-domains but are significantly differ...

www.pnas.org

2

Andy Wolfe @andrewlwolfe.bsky.social · Mar 20

Huge congratulations to Dr. Melinda Diver and her lab on the publication of this outstanding new study, "Transport and InsP8 gating mechanisms of the human inorganic phosphate exporter XPR1" in the journal Nature Communications today!
www.nature.com/articles/s41...

Transport and InsP8 gating mechanisms of the human inorganic phosphate exporter XPR1. Zhu Q, Yaggi MF, Jork N, Jessen HJ, and Diver MM. Nature Communications. Published online March 20, 2025.

3

Andy Wolfe @andrewlwolfe.bsky.social · Mar 7

I am thrilled that our review about the RNA-binding protein IMP2 was published today! Congratulations to my co-authors Jessica Das, Ottavia Busia-Bourdain, and Khizr Khan.
doi.org/10.3390/ijms...

The RNA-binding protein IMP2 reads m6A modifications to regulate target RNAs. When IMP2 changes, the many RNAs that it regulates change too, like a spider vibrating the strands of its web.

1

Reposted by Andy Wolfe

Science Magazine @science.org · Jan 31

A long-awaited nonopioid pain drug has won approval from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain.

Nonopioid drug for acute pain wins FDA approval

Ongoing trials will reveal whether suzetrigine is also effective against chronic pain

scim.ag

1 22 90

Reposted by Andy Wolfe

NEJM.org @nejm.org · Jan 21

Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients. Learn more in a new Clinical Implications of Basic Research article: nej.md/4aia1Bv

#MedSky #Oncology

KRAS Oncoprotein Signaling in Cancer | NEJM

Recent studies provide new insights into signaling by mutant KRAS, inhibitors of which have provided modest benefits for patients.

nej.md

3 12

Andy Wolfe @andrewlwolfe.bsky.social · Dec 20

A new post in Science Careers for our open-rank faculty search at the Hunter College Dept of Biological Sciences: jobs.sciencecareers.org/job/668588/o...

2 6

Andy Wolfe @andrewlwolfe.bsky.social · Dec 13

It's been a delight to be a Mentor to a Postbac Scholar in Damon Runyon SPARK this year. College seniors interested in paid full time cancer research next year - I encourage you to apply to SPARK. @damonrunyon.org damonrunyon.org/for-scientists/application-guidelines/research

Damon Runyon Scholars Program for Advancing Research and Knowledge | Damon Runyon

damonrunyon.org

1 11

Andy Wolfe @andrewlwolfe.bsky.social · Dec 9

Do you love science and want research experience before your next step? NY-RaMP is a 1 year paid opportunity for recent college graduates to do research in my lab or another lab at Hunter College. Learn more at a free webinar on Wed Dec 11 at 3 PM EST nyramp.org/webinars

1 13

Andy Wolfe @andrewlwolfe.bsky.social · Dec 4

Cancer researchers: Are you a postdoc ready to launch your own lab? Or an Assistant/Associate/Full Professor seeking a change of scene? The Biological Sciences dept at Hunter College in New York City is hiring! Apply to our new open rank faculty search: bit.ly/huntercollegebiology

Jobs | City University of New York

bit.ly

1 6

Andy Wolfe @andrewlwolfe.bsky.social · Nov 24

What an amazing team!

2 10